Chandeze et al. [26] have pointed out in their study that after the implementation of VATS combined with short course of high-dose GCS and immunosuppressants in patients with late-onset and severe MG, the CTLA4 levels in Treg cells of the patients who underwent the treatment were (16.42 ± 2.23)%, which were significantly higher than (11.76 ± 2.15)% of the patients who were treated with VATS alone, illustrating that the combination therapy can enhance the Treg cells levels in the peripheral blood of MG patients and improve therapeutic effect. Here, CTLA4 is linked to myasthenia gravis.